De Boer AJ - Search Results

1

Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.

Van de Wiel-van Kemenade E, Te Velde AA, De Boer AJ, Weening RS, Fischer A, Borst J, Melief CJ, Figdor CG. Van de Wiel-van Kemenade E, et al. Among authors: de boer aj. Eur J Immunol. 1992 Jun;22(6):1467-75. doi: 10.1002/eji.1830220620. Eur J Immunol. 1992. PMID: 1376259 Free article.

2

Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA.

van de Wiel-van Kemenade E, van Kooyk Y, de Boer AJ, Huijbens RJ, Weder P, van de Kasteele W, Melief CJ, Figdor CG. van de Wiel-van Kemenade E, et al. Among authors: de boer aj. J Cell Biol. 1992 Apr;117(2):461-70. doi: 10.1083/jcb.117.2.461. J Cell Biol. 1992. PMID: 1560035 Free PMC article.

3

Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.

Adema GJ, de Boer AJ, van 't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG. Adema GJ, et al. Among authors: de boer aj. Am J Pathol. 1993 Dec;143(6):1579-85. Am J Pathol. 1993. PMID: 7504884 Free PMC article.

4

Molecular characterization of the melanocyte lineage-specific antigen gp100.

Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. Adema GJ, et al. Among authors: de boer aj. J Biol Chem. 1994 Aug 5;269(31):20126-33. J Biol Chem. 1994. PMID: 7519602 Free article.

5

Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line.

Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ, Figdor CG. Bakker AB, et al. Among authors: de boer aj. Int J Cancer. 1995 Jul 4;62(1):97-102. doi: 10.1002/ijc.2910620118. Int J Cancer. 1995. PMID: 7541395 Free article.

6

Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.

Bakker AB, Marland G, de Boer AJ, Huijbens RJ, Danen EH, Adema GJ, Figdor CG. Bakker AB, et al. Among authors: de boer aj. Cancer Res. 1995 Nov 15;55(22):5330-4. Cancer Res. 1995. PMID: 7585596

7

Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG. van de Wiel-van Kemenade E, et al. Among authors: de boer aj. J Immunol. 1993 Jul 15;151(2):767-76. J Immunol. 1993. PMID: 7687622

8

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. Bakker AB, et al. Among authors: de boer aj. J Exp Med. 1994 Mar 1;179(3):1005-9. doi: 10.1084/jem.179.3.1005. J Exp Med. 1994. PMID: 8113668 Free PMC article.

9

Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG. Vlasveld LT, et al. Among authors: de boer aj. Cancer Immunol Immunother. 1993;36(3):210-3. doi: 10.1007/BF01741094. Cancer Immunol Immunother. 1993. PMID: 8439983 Free PMC article.

10

pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.

Adema GJ, Bakker AB, de Boer AJ, Hohenstein P, Figdor CG. Adema GJ, et al. Among authors: de boer aj. Br J Cancer. 1996 May;73(9):1044-8. doi: 10.1038/bjc.1996.202. Br J Cancer. 1996. PMID: 8624261 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page